Frank Nocken: FDA Approves Caplacizumab Therapy for Pediatric Acquired TTP
Frank Nocken, Independent Consultant for Scientific Innovation Management, shared a post on LinkedIn:
“‘The FDA has approved Cablivi (caplacizumab) for injection to treat pediatric patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.’
‘Caplacizumab therapy is nanobody-based and built on small antibody fragments derived from heavy-chain-only antibodies, that targets von Willebrand factor, a protein that plays a central role in platelet adhesion and clot formation in aTTP.
It works by binding to the A1 domain of von Willebrand factor, blocking its interaction with platelets and helping to reduce the microvascular clots that define the disease.'”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 15:07Carlos Henrique Del Carlo: HFpEF Reimagined as an Adipose Tissue Driven Disease
-
Apr 14, 2026, 15:05Matteo Foschi: ASPERA-R Study Reveals Competing Causes Of Breakthrough Stroke On Anticoagulation
-
Apr 14, 2026, 14:48Samwel Mikaye: From Virchow’s Triad to Prevention of PE in Patients with DVT
-
Apr 14, 2026, 14:43Chokri Ben Lamine: Diamond – Blackfan Anemia and Congenital Dyserythropoietic Anemia Pearls
-
Apr 14, 2026, 14:14From the Clinical Transfusion Working Party – 2025 International Platelet Transfusion Guidelines – ISBT
-
Apr 14, 2026, 13:48Antoine Francis: This Is What a Donation Actually Becomes
-
Apr 14, 2026, 13:09Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
-
Apr 14, 2026, 13:01Shahzaib Maqbool: Preeclampsia Through a Hematology Lens
-
Apr 14, 2026, 12:46Rosa Hart: Inside Pediatric Stroke Recovery with Dr. Catherine Schuster